GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (LTS:0QM8) » Definitions » EPS without NRI

Acino Holding AG (LTS:0QM8) EPS without NRI : CHF-5.15 (TTM As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Acino Holding AG EPS without NRI?

Acino Holding AG's earnings per share without non-recurring items for the six months ended in Dec. 2013 was CHF-5.15. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2013 was CHF-5.15.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Acino Holding AG's EPS without NRI or its related term are showing as below:

LTS:0QM8's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Acino Holding AG's EPS (Diluted) for the six months ended in Dec. 2013 was CHF-5.15. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2013 was CHF-5.15.

Acino Holding AG's EPS (Basic) for the six months ended in Dec. 2013 was CHF-5.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2013 was CHF-5.15.


Acino Holding AG EPS without NRI Historical Data

The historical data trend for Acino Holding AG's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acino Holding AG EPS without NRI Chart

Acino Holding AG Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.80 1.82 2.22 2.67 -5.15

Acino Holding AG Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 15.80 1.82 2.22 2.67 -5.15

Competitive Comparison of Acino Holding AG's EPS without NRI

For the Drug Manufacturers - General subindustry, Acino Holding AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acino Holding AG's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Acino Holding AG's PE Ratio without NRI falls into.



Acino Holding AG EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2013 was CHF-5.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acino Holding AG  (LTS:0QM8) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Acino Holding AG EPS without NRI Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Acino Holding AG (LTS:0QM8) Business Description

Traded in Other Exchanges
N/A
Address
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (LTS:0QM8) Headlines

No Headlines